Health Care & Life Sciences » Biotechnology | ReNeuron Group PLC

ReNeuron Group PLC | Balance Sheet

Fiscal year is April-March. All values GBP Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
20,917.00
12,382.00
60,709.00
53,061.00
37,411.00
Total Accounts Receivable
1,140.00
1,480.00
3,677.00
5,075.00
4,295.00
Other Current Assets
290.00
192.00
508.00
-
-
Total Current Assets
22,347.00
14,054.00
64,894.00
58,136.00
41,706.00
Net Property, Plant & Equipment
225.00
161.00
361.00
724.00
726.00
Total Investments and Advances
-
-
5,000.00
-
-
Long-Term Note Receivable
275.00
281.00
11.00
-
-
Intangible Assets
1,272.00
1,591.00
1,591.00
-
186.00
Total Assets
24,119.00
16,087.00
71,857.00
58,860.00
42,618.00
ST Debt & Current Portion LT Debt
1.00
1.00
1.00
-
-
Accounts Payable
1,159.00
1,059.00
1,502.00
1,817.00
1,924.00
Other Current Liabilities
876.00
1,285.00
2,696.00
3,886.00
4,025.00
Total Current Liabilities
2,036.00
2,345.00
4,199.00
5,703.00
5,949.00
Long-Term Debt
2.00
1.00
-
-
-
Provision for Risks & Charges
364.00
605.00
-
-
-
Total Liabilities
2,402.00
2,951.00
4,199.00
5,703.00
5,949.00
Common Equity (Total)
21,717.00
13,136.00
67,658.00
53,157.00
36,669.00
Total Shareholders' Equity
21,717.00
13,136.00
67,658.00
53,157.00
36,669.00
Total Equity
21,717.00
13,136.00
67,658.00
53,157.00
36,669.00
Liabilities & Shareholders' Equity
24,119.00
16,087.00
71,857.00
58,860.00
42,618.00

About ReNeuron Group

View Profile
Address
Pencoed Business Park
Pencoed BJ CF35 5HY
United Kingdom
Employees -
Website http://reneuron.com
Updated 07/08/2019
ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. It develops its core stem cell assets such as CTX neural cell line and human retinal progenitor cells. The company was founded by John David Sinden in 1997 and is headquartered in Pencoed, the United Kingdom.